Results - Financial year for the quarter ended 30 June, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medico Intercontinental Ltd reported standalone Q1 FY26 revenue from operations of Rs 1,306.68 lakhs, up ~13.4% YoY from Rs 1,151.99 lakhs. Total standalone revenue grew to Rs 1,370.86 lakhs (~18% YoY). Standalone profit after tax rose to Rs 55.60 lakhs from Rs 49.71 lakhs YoY, with EPS at Rs 0.56 vs Rs 0.50. On a consolidated basis, revenue from operations was Rs 2,135.49 lakhs (~11% YoY), but the company swung to a consolidated loss of Rs 248.80 lakhs versus a profit of Rs 108.32 lakhs in Q1 FY25, driven mainly by Rs 304.40 lakhs in losses at the subsidiary level. Net loss attributable to owners was Rs 67.82 lakhs (EPS: -Rs 0.68). The board also approved the AGM for September 30, 2025. Auditor M/s V. Goswami & Co issued an unmodified (clean) review opinion. Prior period consolidated figures have been restated following a change in accounting policy for the Medico Lab joint venture, moving from proportionate consolidation to the equity method under Ind AS 28.
Standalone performance remains healthy with steady revenue and profit growth, but the sharp swing into consolidated losses highlights weakness in subsidiaries and could weigh on stock sentiment. Investors should note the restated comparatives and watch whether subsidiary-level losses are one-time or structural.